NHS Logo

Management of sickle cell disease in pregnancy (Record no. 75457)

MARC details
000 -LEADER
fixed length control field 03720cam a2200157 4500
001 - CONTROL NUMBER
control field NMDX6046
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 120401t2011 xxu||||| |||| 00| 0 eng d
080 ## - UNIVERSAL DECIMAL CLASSIFICATION NUMBER
Universal Decimal Classification number WH 170 RCO
110 ## - MAIN ENTRY--CORPORATE NAME
Corporate name or jurisdiction name as entry element Royal College of Obstetricians and Gynaecologists
245 ## - TITLE STATEMENT
Title Management of sickle cell disease in pregnancy
Remainder of title Green-top Guideline No. 61
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc. 2011
500 ## - GENERAL NOTE
General note Monograph
500 ## - GENERAL NOTE
General note 20 p.
520 ## - SUMMARY, ETC.
Summary, etc. <div><span style="font-size: 8pt;">The purpose of this guideline is to describe the management of pregnant women with sickle cell disease (SCD). It will include preconceptual screening and antenatal, intrapartum and postnatal management. It will not cover the management of women with sickle cell trait.</span></div><div><span style="font-size: 8pt;"><br /></span></div><div><span style="font-size: 8pt;">SCD is a group of inherited single-gene autosomal recessive disorders caused by the ‘sickle’ gene, which affects haemoglobin structure. SCD has its origins in sub-Saharan Africa and the Middle East, hence it is most prevalent in individuals of African descent as well as in the Caribbean, Middle East, parts of India and the Mediterranean, and South and Central America. Owing to population migration, SCD is now of increasing importance worldwide and there are increasing numbers of affected individuals in Europe and the USA. The term SCD includes sickle cell anaemia (HbSS) and the heterozygous conditions of haemoglobin S and other clinically abnormal haemoglobins. These include combination with haemoglobin C (giving HbSC), combination with beta thalassaemia (giving HbSB thalassaemia) and combination with haemoglobin D, E or O-Arab. All of these genotypes will give a similar clinical phenotype of varying  severity. Haemoglobin S combined withnormal haemoglobin (A), known as sickle trait (AS), is asymptomatic, except for a possible increased risk of urinary tract infections and microscopic haematuria, and is not considered further in this guideline. SCD is the most common inherited condition worldwide. About 300 000 children with SCD are born each year; two-thirds of these births are in Africa. In the UK, it is estimated that there are 12 000–15 000 affected individuals and over 300 infants born with SCD in the UK each year who are diagnosed as part of the neonatal screening programme. There are approximately 100–200 pregnancies in women with SCD per year in the UK; pregnancy outcome in this group is currently being assessed by the UK Obstetric Surveillance System [https://www.npeu.ox.ac.uk/ukoss/completed-surveillance].</span></div><div><span style="font-size: 8pt;"> </span></div><div><span style="font-size: 8pt;">The pathophysiology of SCD is a consequence of polymerisation of the abnormal haemoglobin in low-oxygen conditions, which leads to the formation of rigid and fragile sickle-shaped red cells. These cells are prone to increased breakdown, which causes the haemolytic anaemia, and to vaso-occlusion in the small blood vessels, which causes most of the other clinical features, including acute painful crises. Other complications of SCD include stroke, pulmonary hypertension, renal dysfunction, retinal disease, leg ulcers, cholelithiasis and avascular necrosis (which commonly affects the femoral head and may necessitate hip replacement). SCD was previously associated with a high early mortality rate, but now the majority of children born with SCD in the UK live to reproductive age and average life expectancy is at least the mid-50s.</span></div>
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://www.rcog.org.uk/files/rcog-corp/GTG6111042013.pdf">http://www.rcog.org.uk/files/rcog-corp/GTG6111042013.pdf</a>
Holdings
Withdrawn status Lost status Damaged status Not for loan Home library Current library Shelving location Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
        Ferriman information and Library Service (North Middlesex) Ferriman information and Library Service (North Middlesex) Shelves 03/01/2014   WH 170 RCO mx17937117 07/06/2022 07/06/2022 Book
London Health Libraries Consortium Privacy notice and Membership terms and conditions